Startups in the Triangle have a new potential source for cash. Backers announced Thursday the launch of the RTP Angel Fund, saying they already have raised $3 million with $2 million more still being sought. Here are the details.
Zogenix Launches Dravet Syndrome Community Photo Sharing Charitable Campaign and Contest to Benefit the Dravet Syndrome Foundation and the Epilepsy Foundation
News provided by
Share this article
FINTEPLA
EMERYVILLE, Calif., May 19, 2021 /PRNewswire/ Zogenix, a global biopharmaceutical company developing rare disease therapies, today launched the FINTEPLA Photo Diary, a community sharing, charitable campaign and contest. To participate in the charitable campaign and contest, Zogenix is asking the Dravet syndrome community to share photos of their everyday moments in life with fewer seizures on FINTEPLA
® (fenfluramine) from now through June 9, 2021. From June 21 – July 19, 2021, each time a member of the public Likes or shares a featured photo in the FINTEPLA Photo Diary hosted on the FINTEPLA Facebook page, Zogenix will proudly donate $25 to support advocacy organizations that serve the Dravet syndrome community in the United States (US). Up to $50,000 will be donated an
Zogenix Puts Focus On Safety In Seizure Patients
By Ed Miseta, Chief Editor, Clinical Leader
Follow Me On Twitter @EdClinical
Zogenix has been part of the drug development industry for about 12 years. The public company, located just across the Bay Bridge from San Francisco, has now been through a couple of iterations. It started out as a pain treatment company but quickly realized that was not an area where it could make a transformational difference in patients lives. In 2015, after a few years in business, the company divested all pain assets, reduced the headcount to 30, and opted to retool the organization to focus on rare diseases.